Home WebinarsFormulating the Future: LNP Strategies from Lipid Screening through Commercial Readiness

Formulating the Future: LNP Strategies from Lipid Screening through Commercial Readiness

WEBINAR

This symposium explores the full lifecycle of lipid nanoparticle (LNP) formulation, from preclinical lipid screening and formulation optimization to clinical and commercial manufacturing. Experts will share real-world insights into tech transfer, process development, and analytical tools that support a broad range of nucleic acid payloads. Attendees will gain practical perspectives on how to accelerate innovation and ensure scalability at every phase of development.

In this symposium, you will:

Explore how to screen and optimize LNP formulations for nucleic acid payloads to set preclinical programs on the path to success
Learn strategies to develop a scalable GMP LNP manufacturing process to advance through the clinic
Discover the rational design of lipid nanoparticles enabling RNA delivery beyond the liver

Speakers

Bhuvaneshwar Vaidya, Ph.D.

Merck

Manager, Process Development, LNP CDMO Center of Excellence

Bhuvaneshwar Vaidya, Ph.D., is leading the process development team in the Center of Excellence LNP CDMO at Merck. He focuses on the process development and optimization of LNPs for nucleic acid modalities. After receiving his Ph.D. in pharmaceutical sciences, he continued as a postdoctoral researcher with a focus on developing various novel (nano) drug delivery systems, including lipid-, polymer- and surface-functionalized nanoparticles for targeted and controlled drug delivery. He has authored more than 50 peer-reviewed articles in leading journals and more than 10 book chapters in the field of drug delivery sciences.

Johanna Simon, Ph.D.

Merck

Principial Scientist

Johanna Simon, Ph.D., is heading the formulation discovery and analytical characterization team within the early formulation screening service at Merck. Her work focuses on the preclinical formulation development of custom lipid nanoparticles for nucleic acid modalities. After receiving her Ph.D. in chemistry, Johanna has continued her scientific career as a postdoctoral researcher with a focus on developing lipid-, polymer- and antibody-functionalized nanoparticles for targeted drug delivery in vivo. Johanna has authored 50-plus peer-reviewed articles in leading journals in the field of drug delivery sciences.

Dominik Witzigmann, Ph.D.

NanoVation Therapeutics (NVTx)

Co-Founder & President

Dominik Witzigmann, Ph.D., is an entrepreneurial scientist and 2024 Highly Cited Researcher as one of the world's leading researchers in nucleic acid delivery. He held research positions at leading institutions (safety/tox, RNAi & cancer, targeted DNA delivery, RNA-based genome editing) and joined Professor Pieter Cullis to focus on extrahepatic RNA delivery. He held leadership roles in Canada’s NanoMedicines Innovation Network (NMIN) and was on the CRS Gene Delivery and Genome Editing Focus Group Board. He co-founded NanoVation Therapeutics to advance next-generation LNP technologies for genetic medicines.